Last week, the company held a grand opening ceremony for a new $4.3 million (€4 million) R&D facility in Blackrock, Dublin. BD also announced an additional $32.1 million (€30 million) investment to expand its Enniscorthy, Wexford manufacturing facility.
The Blackrock facility’s focus centers around the commercialization of BD’s first on-body injector device, the Evolve. It also serves as the regional base of operations for sales, technical service and corporate functional support teams.
Get the full story at our sister site, Drug Delivery Business News.
